Acute hepatitis C: current status and remaining challenges.

[1]  N. Shire,et al.  Acute Hepatitis C Virus Infection: a Chronic Problem Epidemiology and Natural History of Hcv Infection , 2007 .

[2]  M. Manns,et al.  [Injuries from needles contaminated with hepatitis C virus: how high is the risk of seroconversion for medical personnel really?]. , 2007, Der Internist.

[3]  F. D. De Rosa,et al.  Twelve-week treatment of acute hepatitis C virus with pegylated interferon- alpha -2b in injection drug users. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  P. Klenerman,et al.  Tracking Virus-Specific CD4+ T Cells during and after Acute Hepatitis C Virus Infection , 2007, PloS one.

[5]  F. Carrilho,et al.  Acute hepatitis C virus infection assessment among chronic hemodialysis patients in the Southwest Parana State, Brazil , 2007, BMC public health.

[6]  L. Finelli,et al.  Surveillance for acute viral hepatitis--United States, 2005. , 2007, Morbidity and mortality weekly report. Surveillance summaries.

[7]  J. Medina-Pestana,et al.  Interferon-alpha therapy within the first year after acute hepatitis C infection in hemodialysis patients: efficacy and tolerance , 2007, European journal of gastroenterology & hepatology.

[8]  F. D. De Rosa,et al.  A short course of pegylated interferon‐α in acute HCV hepatitis , 2007 .

[9]  A. Perelson,et al.  Acute Hepatitis C in Patients Receiving Hemodialysis , 2007, Renal failure.

[10]  M. Massari,et al.  Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  G. Lauer,et al.  Outcomes and treatment of acute hepatitis C virus infection in a United States population. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  J. Kaldor,et al.  Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug users , 2006, Epidemiology and Infection.

[13]  C. Katlama,et al.  Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients , 2006, AIDS.

[14]  N. Afdhal,et al.  Duration of peginterferon therapy in acute hepatitis C: A randomized trial , 2006, Hepatology.

[15]  N. Afdhal,et al.  Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. , 2006, Gastroenterology.

[16]  M. Manns,et al.  Early monotherapy with pegylated interferon alpha‐2b for acute hepatitis C infection: The HEP‐NET acute‐HCV‐II study , 2006, Hepatology.

[17]  F. D. De Rosa,et al.  Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C. , 2006, The Journal of antimicrobial chemotherapy.

[18]  C. Rouzioux,et al.  Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy , 2006, AIDS.

[19]  J. Kaldor,et al.  Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies , 2006, Journal of viral hepatitis.

[20]  B. Gazzard,et al.  Transmission of Hepatitis C Virus Among HIV-Positive Homosexual Men and Response to a 24-Week Course of Pegylated Interferon and Ribavirin , 2005, Journal of acquired immune deficiency syndromes.

[21]  A. Al-Harbi,et al.  Treatment of acute hepatitis C virus infection with alpha interferon in patients on hemodialysis. , 2005, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia.

[22]  M. Mondelli,et al.  Acute hepatitis C: diagnosis and management. , 2005, Journal of hepatology.

[23]  T. Santantonio,et al.  Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. , 2005, Journal of hepatology.

[24]  F. Negro,et al.  Barriers to interferon-α therapy are higher in intravenous drug users than in other patients with acute hepatitis C , 2005 .

[25]  B. Rehermann,et al.  Acute Hepatitis C: A Multifaceted Disease , 2005, Seminars in liver disease.

[26]  F. Carrat,et al.  Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. , 2004, JAMA.

[27]  T. Nakano,et al.  Cellular Immune Responses in Seronegative Sexual Contacts of Acute Hepatitis C Patients , 2004, Journal of Virology.

[28]  F. Fabrizi,et al.  Hepatitis C infection associated with renal disease and chronic renal failure. , 2004, Seminars in liver disease.

[29]  M. Manns,et al.  High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection , 2004, Journal of medical virology.

[30]  H. Van Vlierberghe,et al.  Treatment of acute hepatitis C with interferon α‐2b: early initiation of treatment is the most effective predictive factor of sustained viral response , 2004, Alimentary pharmacology & therapeutics.

[31]  M. Manns,et al.  Long‐term follow‐up after successful interferon therapy of acute hepatitis C , 2004, Hepatology.

[32]  C. Graham,et al.  Pegylated interferon α therapy in acute hepatitis C: Relation to hepatitis C virus–specific T cell response kinetics , 2004, Hepatology.

[33]  H. Nomura,et al.  Short‐term interferon‐alfa therapy for acute hepatitis C: A randomized controlled trial , 2004, Hepatology.

[34]  L. Seeff,et al.  Aasld Practice Guideline Diagnosis, Management, and Treatment of Hepatitis C , 2003 .

[35]  A. Craxì,et al.  When and how to treat acute hepatitis C? , 2003, Journal of hepatology.

[36]  Charles M. Rice,et al.  HCV Persistence and Immune Evasion in the Absence of Memory T Cell Help , 2003, Science.

[37]  M. Manns,et al.  The German network of excellence for viral hepatitis (Hep‐Net) , 2003, Hepatology.

[38]  N. Gruener,et al.  Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. , 2003, Gastroenterology.

[39]  T. Santantonio,et al.  Natural course of acute hepatitis C: a long-term prospective study. , 2003, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[40]  E. Penner,et al.  Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load , 2003, Hepatology.

[41]  J. Pawlotsky.  Use and interpretation of virological tests for hepatitis C , 2002, Hepatology.

[42]  S. Giampaoli,et al.  Infection rate and spontaneous seroreversion of anti-hepatitis C virus during the natural course of hepatitis C virus infection in the general population , 2002, Gut.

[43]  D. Prati,et al.  An estimate of the current risk of transmitting blood‐borne infections through blood transfusion in Italy , 2002, British journal of haematology.

[44]  F. Chisari,et al.  Determinants of Viral Clearance and Persistence during Acute Hepatitis C Virus Infection , 2001, The Journal of experimental medicine.

[45]  C. Trautwein,et al.  Treatment of acute hepatitis C with interferon alfa-2b. , 2001, The New England journal of medicine.

[46]  T. Wright,et al.  Acute hepatitis C , 2001 .

[47]  P. Klenerman,et al.  CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained , 2000, European journal of immunology.

[48]  M. Cucchiarini,et al.  Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. , 2000, The Journal of infectious diseases.

[49]  Tosti,et al.  Prevention of hepatitis C in Italy: lessons from surveillance of type‐specific acute viral hepatitis , 2000, Journal of viral hepatitis.

[50]  I. Williams,et al.  Epidemiology of hepatitis C in the United States. , 1999, The American journal of medicine.

[51]  T. Santantonio,et al.  Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. , 1999, Gastroenterology.

[52]  H. Margolis,et al.  Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease , 1998 .

[53]  J. M. Calvo Romero,et al.  Gastric adenocarcinoma and kidney transplantation , 1998 .

[54]  Edoardo Cervoni,et al.  Hepatitis C , 1998, The Lancet.

[55]  C. Datz,et al.  High-dose interferon-α2b treatment prevents chronicity in acute hepatitis C , 1996, Digestive Diseases and Sciences.

[56]  Cindy Farquhar,et al.  3 The Cochrane Library , 1996 .

[57]  T. Poynard,et al.  Meta‐analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration , 1996, Hepatology.

[58]  A. Craxì,et al.  Interferon as treatment for acute hepatitis C , 1996, Digestive Diseases and Sciences.

[59]  T. Santantonio,et al.  Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection , 1995, The Lancet.

[60]  X. Forns,et al.  Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. , 2008, Journal of hepatology.

[61]  S. Sauleda,et al.  The changing epidemiology of hepatitis C virus infection in Europe. , 2008, Journal of hepatology.

[62]  Michael J. Rausch,et al.  Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals. , 2006, Antiviral therapy.

[63]  J. McHutchison,et al.  American Gastroenterological Association technical review on the management of hepatitis C. , 2006, Gastroenterology.

[64]  L. Seeff.  Management and Treatment of Hepatitis C , 2004 .

[65]  J. Montaner,et al.  Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. , 2004, The New England journal of medicine.

[66]  J. Bartlett.  Peginterferon alfa-2a Plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-Co-infected persons , 2004 .

[67]  Y. Jeong,et al.  Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection , 2003 .

[68]  N. Ozdemir,et al.  Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment. , 2001 .

[69]  Inda,et al.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. , 1999, The New England journal of medicine.